crb-701
crb-701: developed by 1 company · 2 clinical trials tracked.
crb-701 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could crb-701 → CRBP affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) Oropharyngeal Carcinoma (OPC); Solid Tumor, Adult | Phase 3 |
Clinical Trials (2)
A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator's Choice of Capecitabine, Cetuximab, or Docetaxel in Participants With Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma Previously Treated With Platinum-based Chemotherapy and a PD-(L)1 Inhibitor
Primary endpoint: Objective Response Rate (%)
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
Primary endpoint: Part A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701
Frequently asked questions
Who is developing crb-701?
crb-701 is being developed by Corbus Pharmaceuticals Holdings, Inc..
How many clinical trials involve crb-701?
BioSniper tracks 2 clinical trials involving crb-701.